VJHemOnc is committed to improving our service to you

ICML 2019 | Pola-G-Len for R/R follicular lymphoma

VJHemOnc is committed to improving our service to you

Catherine Diefenbach

Catherine Diefenbach, MD, NYU Langone, New York, NY, discusses the interim analysis of the Phase Ib/II study of polatuzumab vedotin, obinituzumab and lenalidomide for relapsed/refractory follicular lymphoma (NCT02600897). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter